Randomized, Two Period Crossover Studies in Fed Healthy, Normal Subjects to Compare the Single Dose Bioavailability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Maximum Plasma Concentration (Cmax)
Study Overview
Brief Summary
Subjects to compare the single dose bioavailability of Torrent's Zolpidem Tartrate Tablets 10mg and Ambien® Tablets 10 mg of Sanofi-Synthelabo Inc.
Detailed Description
An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose Bioequivalence Study of Zolpidem Tartrate Tablets containing Zolpidem Tartrate 10 mg ( Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Ambien® Tablets 10 mg containing Zolpidem Tartrate 10 mg (Reference , Sanofi-Synthelabo Inc) in Healthy Human Volunteers Under Fed Condition.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The subjects who qualify for the study should meet the following inclusion criteria.
- •Male and female subjects in the range of 18 - 45 years of age.
- •Subjects having Body Mass Index (BMI) in a range of 18.5 to 24.
- •Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and body temperature)
- •Subjects with normal findings as determined by hematological tests, serum chemistry, urine analysis, ECG and X-ray.
- •Willingness to follow the protocol requirement as evidenced by written, informed consent.
- •Agreeing to, not using any medication prescription and over the counter medicines including vitamins and minerals for 14 days prior to study and during the course of the study.
- •No history or presence of significant alcoholism or drug abuse in the past one year.
- •Non-smokers, ex smokers and light smokers will be included. " Light smokers are defined as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely stopped smoking for at least 3 months.
Exclusion Criteria
- •The subjects who qualify for the study should not meet the following exclusion criteria:
- •Requiring medication for any ailment including enzyme-modifying drugs in the previous 28 days, before day
- •Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
- •History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic diseases.
- •Participation in a clinical drug study or bioequivalence study 90 days prior to present study.
- •History of malignancy or other serious diseases.
- •Refusal to abstain from food for at least ten (10) hours prior to High Fat Breakfast and for additional four (4) hours post dose during each study period.
- •Refusal to abstain from water for at least one (1) hour prior to study drug administration on each study period and for at least two (2) additional hours, post dosing.
- •Any contraindication to blood sampling.
- •Use of xanthine-containing beverages or food and grapefruit juice for 48 hours prior to each drug dose.
- •Blood donation 90 days prior to the commencement of the study.
- •Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.
- •Known history of hypersensitivity to zolpidem Tartrate or to any of the inactive ingredients in the formulation.
- •Refusal to abstain from smoking or consumption of tobacco products 24 hours before dosing until last sample collection of each period.
- •Pregnant and lactating women.
- •Use of prescription medication within 14 days prior to administration of study medication or over the counter products (including natural food supplements,vitamins, garlic as a supplement) within 14 days prior to administration of study medication, except for topical products without systemic absorption.
- •Female subjects whose menstruation cycle coincides with the study periods.
Arms & Interventions
Test
Torrent's Zolpidem TartrateTablets 10 mg
Intervention: Zolpidem Tartrate Tablets 10 mg (Drug)
Reference
Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
Intervention: 'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg (Drug)
Outcomes
Primary Outcomes
Maximum Plasma Concentration (Cmax)
Time Frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.
The maximum or peak concentration that the drug reaches in the plasma
Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
Time Frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.
The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)
The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)
Time Frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.
The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.
Secondary Outcomes
No secondary outcomes reported